Edwards Lifesciences recently announced a final agreement with Becton, Dickinson and Company to sell its entire intensive care product line to them for $4.2 billion in cash. Based on this agreement, Edward will no longer proceed with the previously announced plan to spin off his intensive care business. The transaction is expected to be completed by the end of 2024.